MedTrace Logo

Exendin-9,39 and Satiety After Bariatric Surgery

NCT02779075 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2020-05-01

Study results available
· View outcomes & findings →

Summary

The overall aim of the application is to determine the contribution of the elevated incretin hormone concentrations seen after certain types of bariatric surgery to the regulation of food intake and satiety.

Conditions

Interventions

DRUG

Saline

Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.

DRUG

Exendin-9,39

Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.

Sponsors & Collaborators

  • The Obesity Society

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Adrian Vella · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-07-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02779075 on ClinicalTrials.gov